Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $465

Benzinga · 11/04 12:02
Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $440 to $465.